

Prior Authorization Request Form Fax Back To: (866) 940-7328

Phone: (800) 310-6826

## **Specialty Medication Prior Authorization Cover Sheet**

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <a href="https://www.uhcprovider.com">www.uhcprovider.com</a> for medication fax request forms.)

Patient Information							
Patient's Name:							
Insurance ID:	Date of Birth:	Height: Weight:					
Address:		Apartment #:					
City:	State:	Zip Code:					
Phone Number:	Alternate Phone:	Sex: Male Female					
Provider Information							
Provider's Name:	Provider ID Number:						
Address:	City:	State: Zip Code:					
Suite Number:	Building Number:						
Phone Number:	Fax number:						
Provider's Specialty:							
Medication Information							
Medication:	Quantity:	ICD10 Code:					
Directions:	Diagnosis:	Refills:					
Physician Signature**:		Initial here if DAW:					
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.							
that can be used to facilitate the dispensing and/	or coordination of delivery for th	e requested medication.					
Medication Instructions	or coordination of delivery for th	e requested medication.					
, ,		re requested medication.  ☐ Yes ☐ No					
Medication Instructions							
Medication Instructions  Has the patient been instructed on how to Self-	Administer?	Yes ☐ No					
Medication Instructions  Has the patient been instructed on how to Self- Is this medication a New Start?	Administer?  Initiation Date: / /	Yes □ No					
Medication Instructions  Has the patient been instructed on how to Self-Is this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reservables attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Administer?  Initiation Date: / / sponse to current therapy? ation that would pertain to su	Yes □ No □ Yes □ No □ Date of Last Dose: / / □ Yes □ No pport stated diagnosis.					
Medication Instructions  Has the patient been instructed on how to Self-Is this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reserved:  **Please attach any pertinent clinical informational clinical information may be needed.	Administer?  Initiation Date: / / sponse to current therapy? ation that would pertain to su	Yes □ No □ Yes □ No □ Date of Last Dose: / / □ Yes □ No pport stated diagnosis.					
Medication Instructions  Has the patient been instructed on how to Self-Is this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reservables attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Administer?  Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patients ian Signature" above and comformation"	Yes No  Yes No  Date of Last Dose: / /  Yes No  Pport stated diagnosis. s plan, including medication(s)					
Medication Instructions  Has the patient been instructed on how to Self-Is this medication a New Start?  If continuation please provide the following:  Is there documentation of positive clinical reservable attach any pertinent clinical informational clinical information may be needed previously tried and failed.  Delivery Instructions  Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Internation" and "Patient Internation" and "Patient Internation"	Administer?  Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patients ian Signature" above and comformation" ided free of charge to the patier						



## **Tagrisso - Washington**

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Inform	iation							
First Name:		Last Name:			Member ID:			
Address:								
City:		State: Z			ZIP C	ZIP Code:		
Phone:		DOB:			Allergies:			
Primary Insurance Information:								
Is the requested medication	n 🗆 New or 🗆 C	ontinuati	on of Therapy? If o	continuation, lis	t star	t date:		
Is this patient currently hos	-	Yes □ No	If recently discha	arged, list disch	arge	date:		
Section B - Provider Inform	nation							
First Name:			Last Name:				M.D./D.O.	
Address:			City:		State		ZIP code:	
Phone:	Fax:		NPI #:		Spec	cialty:		
Office Contact Name / Fax a								
Section C - Medical Inform Medication:	ation				St	trength:		
Directions for use:					ا	uantity:		
Diagnosis (Please be specific & provide as much information as possible):					IC	ICD-10 CODE:		
Is this member pregnant?	□ Yes □ No	If yes	s, what is this mem	ber's due date	?			
Section D - Previous Med	lication Trials							
	lication Trials	If yes	s, what is this mem	Dates of The			on for failure /	
Section D - Previous Med	lication Trials							
Section D - Previous Med	lication Trials							
Section D - Previous Med	lication Trials							
Section D - Previous Med	lication Trials							
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	
Section D – Previous Med Medications  Section E – Additional infor	Stre	ngth	Directions  of why preferred n	Dates of The	erapy	disc	ontinuation	



telecopy in error, please notify the sender immediately.

## **Tagrisso - Washington**

PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:				
	Clinical and Drug Speci	fic Information				
All Requests: - What is the patient's diagnosi □ Central Nervous System (CN	s? (check which applies) S) Cancer □ Non-Small Cell Lung Ca	incer (NSCLC)				
- Is the disease recurrent or me  □ Recurrent □ Metastatic	etastatic?   Yes   No (check which	applies)				
Requests for CENTRAL NERVO  - Is the primary disease (tumor   Ves  No		g., EGFR T790M mutation-positive NSCLC)?				
Requests for NON-SMALL CELL - Is the patient's disease: (chec  □ Sensitizing epidermal growth  □ EGFR T790M mutation-position  □ None of the above	k which applies) factor receptor (EGFR) mutation-positiv	ve				
- Will Tagrisso be used as first- therapy? □ Yes □ No	line therapy or subsequent therapy	after disease progression while on Tagrisso				
(TKI) therapy [e.g., Tarceva (e	·	lerance to prior EGFR tyrosine kinase inhibitor fitinib)]? □ Yes □ No (If yes, complete Section D II, and reason for discontinuation)				
Requests for CONTINUATION Of a document of the patient have a document of the patient have a document of the patient of the pa	mented positive clinical response to	Tagrisso therapy? □ Yes □ No				
- Does the patient show evidence of progressive disease while on Tagrisso therapy? □ Yes □ No						
This information is intended only fo	or the use of UnitedHealthcare. If you are r	Date:  ion belonging to the sender and UnitedHealthcare. not the intended recipient, you are hereby notified that his document is prohibited. If you have received this				